Oncomed Pharmaceuticals Inc Reaches New 12-Month Low at $14.50 (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED)’s share price reached a new 52-week low during trading hours on Wednesday, Analyst Ratings Net reports. The company traded as low as $14.50 and last traded at $14.50, with a volume of 205,586 shares traded. The stock had previously closed at $15.60.
Several analysts have recently commented on the stock. Analysts at BMO Capital Markets initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “outperform” rating and a $32.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “outperform” rating on the stock. Finally, analysts at Piper Jaffray Cos. initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “overweight” rating and a $19.84 price target on the stock.
Oncomed Pharmaceuticals has a 52-week low of $15.00 and a 52-week high of $31.00. The stock has a 50-day moving average of $16.47 and a 200-day moving average of $18.30. The company’s market cap is $388.2 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.81. The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $8.31 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-0.67 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.